Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 9/2020

01-09-2020 | Opioid-Related Disorders | Original Research

Barriers to Medications for Opioid Use Disorder Among Veterans Involved in the Legal System: a Qualitative Study

Authors: Andrea K. Finlay, PhD, Erica Morse, MA, Matthew Stimmel, PhD, Emmeline Taylor, BS, Christine Timko, PhD, Alex H. S. Harris, PhD, David Smelson, PsyD, Mengfei Yu, MS, Jessica Blue-Howells, MSW, Ingrid A. Binswanger, MD

Published in: Journal of General Internal Medicine | Issue 9/2020

Login to get access

Abstract

Background

Veterans involved in the legal system are at high risk for overdose but have lower receipt of medications for opioid use disorder than other veterans.

Objective

The study aimed to understand barriers to medication access from the perspective of legally involved veterans with opioid use disorder and people who work with these veterans in the Veterans Health Administration (VHA) and the legal system.

Design

This national qualitative study interviewed veterans and stakeholders from 14 geographically diverse VHA facilities to explore perceptions of barriers to medications for opioid use disorder.

Participants

Participants included veterans with a history of opioid use disorder and legal involvement (n = 18), VHA Veterans Justice Programs Specialists (n = 15), VHA and community substance use disorder treatment providers (n = 5), and criminal justice staff (n = 12).

Approach

We conducted interviews based on the Consolidated Framework for Implementation Research. Interview transcripts were analyzed using a team-based approach.

Key Results

Four key barriers, noted by group, were identified: (1) a preference for counseling along with or instead of medications (veterans, Specialists, treatment providers, criminal justice staff); (2) concerns about veterans using medications without a prescription, selling them, or providing them to others (veterans, Specialists, treatment providers, criminal justice staff); (3) concerns about perceived stigma towards medication use (veterans, Specialists, treatment providers, criminal justice staff); and (4) concerns about medication discontinuation after recurrent opioid use (veterans, criminal justice staff). A fifth theme, education, was noted by all stakeholders except providers as important to facilitating use of medications for opioid use disorder. All five themes mapped to the framework construct of knowledge and beliefs about the intervention.

Conclusions

Based on identified barriers, interventions focused on enhancing medication knowledge, reducing stigma towards use of medications, and increasing knowledge that opioid use may recur during treatment may help increase access to medication for veterans with legal involvement.
Appendix
Available only for authorised users
Literature
1.
Wortzel HS, Blatchford P, Conner L, Adler LE, Binswanger IA. Risk of death for veterans on release from prison. J Am Acad Psychiatry Law. 2012;40(3):348-54.PubMedPubMedCentral
2.
Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.PubMedPubMedCentral
3.
Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018 Aug 7;169(3):137-45.PubMedPubMedCentral
4.
Coviello DM, Cornish JW, Lynch KG, Boney TY, Clark CA, Lee JD, et al. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus. 2012;33(1):48-59.PubMedPubMedCentral
5.
Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction. 2005;100(6):820-8.PubMed
6.
Gryczynski J, Kinlock TW, Kelly SM, O’Grady KE, Gordon MS, Schwartz RP. Opioid agonist maintenance for probationers: patient-level predictors of treatment retention, drug use, and crime. Subst Abus. 2012;33(1):30-9.PubMed
7.
Kelly SM, O’Grady K E, Jaffe JH, Gandhi D, Schwartz RP. Improvements in outcomes in methadone patients on probation/parole regardless of counseling early in treatment. J Addict Med. 2013;7(2):133-8.PubMedPubMedCentral
8.
Russolillo A, Moniruzzaman A, McCandless LC, Patterson M, Somers JM. Associations between methadone maintenance treatment and crime: a 17-year longitudinal cohort study of Canadian provincial offenders. Addiction. 2018 Apr;113(4):656-67.PubMed
9.
Russolillo A, Moniruzzaman A, Somers JM. Association of methadone treatment with substance-related hospital admissions among a population in Canada with a history of criminal convictions. JAMA Netw Open. 2019;2(3):e190595.PubMedPubMedCentral
10.
Evans EA, Zhu Y, Yoo C, Huang D, Hser YI. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder. Addiction. 2019;114(8):1396-404.PubMedPubMedCentral
11.
Larney S, Toson B, Burns L, Dolan K. Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration. Addiction. 2012;107(2):372-80.PubMed
12.
Gisev N, Shanahan M, Weatherburn DJ, Mattick RP, Larney S, Burns L, et al. A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence. Addiction. 2015;110(12):1975-84.PubMed
13.
Finlay AK, Harris AH, Rosenthal J, Blue-Howells J, Clark S, McGuire J, et al. Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients. Drug Alcohol Depend. 2016;160:222-6.PubMedPubMedCentral
14.
Fox AD, Maradiaga J, Weiss L, Sanchez J, Starrels JL, Cunningham CO. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder. Addict Sci Clin Pract. 2015;10(1):2.PubMedPubMedCentral
15.
Larney S, Zador D, Sindicich N, Dolan K. A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South Wales, Australia. Drug Alcohol Rev. 2017;36(3):305-10.PubMed
16.
Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev. 2011;4(1):28-41.PubMedPubMedCentral
17.
Rosenblatt RA, Andrilla CH, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23-6.PubMedPubMedCentral
18.
Oliva EM, Maisel NC, Gordon AJ, Harris AH. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep. 2011;13(5):374-81.PubMedPubMedCentral
19.
Finlay AK, Wong JJ, Ellerbe LS, Rubinsky A, Gupta S, Bowe TR, et al. Barriers and facilitators to implementation of pharmacotherapy for opioid use disorders in VHA residential treatment programs. J Stud Alcohol Drugs. 2018;79(6):909-17.PubMedPubMedCentral
20.
Friedmann PD, Hoskinson R, Gordon M, Schwartz R, Kinlock T, Knight K, et al. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Subst Abus. 2012;33(1):9-18.PubMedPubMedCentral
21.
Matusow H, Dickman SL, Rich JD, Fong C, Dumont DM, Hardin C, et al. Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes. J Subst Abuse Treat. 2013;44(5):473-80.PubMed
22.
Reichert J, Gleicher L. Probation clients’ barriers to access and use of opioid use disorder medications. Health Justice. 2019;7(1):10.PubMedPubMedCentral
23.
McElrath K. Medication-assisted treatment for opioid addiction in the United States: Critique and commentary. Subst Use Misuse. 2018;53(2):334-43.PubMed
24.
Department of Veterans Affairs. Uniform Mental Health Services in VA medical centers and clinics. VHA Handbook 1160.1. Washington, DC: US Department of Veterans Affairs, Veterans Health Administration; 2008.
25.
Blue-Howells JH, Clark SC, van den Berk-Clark C, McGuire JF. The U.S. Department of Veterans Affairs Veterans Justice Programs and the sequential intercept model: case examples in national dissemination of intervention for justice-involved veterans. Psychol Serv. 2013;10(1):48-53. doi:https://​doi.​org/​10.​1037/​a0029652CrossRefPubMed
26.
Finlay AK, Binswanger IA, Timko C, Smelson D, Stimmel MA, Yu M, et al. Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science. J Subst Abuse Treat. 2018 Dec;95:43-7.PubMedPubMedCentral
27.
Finlay AK, Harris AHS, Timko C, Yu M, Smelson D, Stimmel M, et al. Disparities in access to medications for opioid use disorder in the Veterans Health Administration. Manuscript submitted for publication. 2019.
28.
Hennink MM, Kaiser BN, Marconi VC. Code saturation versus meaning saturation: how many interviews are enough? Qual Health Res. 2017 Mar;27(4):591-608.PubMed
29.
Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implementation Sci. 2009;4:50.
30.
Manuel JK, Hagedorn HJ, Finney JW. Implementing evidence-based psychosocial treatment in specialty substance use disorder care. Psychol Addict Behav. 2011;25(2):225-37.PubMedPubMedCentral
31.
Sorensen JL, Kosten T. Developing the tools of implementation science in substance use disorders treatment: applications of the Consolidated Framework for Implementation Research. Psychol Addict Behav. 2011;25(2):262-8.PubMedPubMedCentral
32.
Finlay AK, Ellerbe LS, Wong JJ, Timko C, Rubinsky AD, Gupta S, et al. Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs. J Subst Abuse Treat. 2017;77:38-43.PubMedPubMedCentral
33.
Atlas.ti Scientific Software Development GmbH. Atlas.ti Version 8 [Computer Software]. Berlin, Germany: Scientific Software Development; 2019.
34.
Bryant A, Charmaz K, editors. The Sage Handbook of Grounded Theory. Newbury Park, CA: Sage Publications; 2010.
35.
Huhn AS, Tompkins DA, Dunn KE. The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use. Drug Alcohol Depend. 2017 Nov 1;180:279-85.PubMedPubMedCentral
36.
Uebelacker LA, Bailey G, Herman D, Anderson B, Stein M. Patients’ beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no medication-assisted therapy following inpatient opioid detoxification. J Subst Abuse Treat. 2016 Jul;66:48-53.PubMedPubMedCentral
37.
Winkelman TNA, Chang VW, Binswanger IA. Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid use. JAMA Netw Open. 2018;1(3):e180558.PubMedPubMedCentral
38.
Department of Veterans Affairs & Department of Defense. VA/DoD clinical practice guideline for the management of substance use disorders. Washington, DC: Authors; 2015.
39.
Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2011 (10):CD004147.
40.
Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358-67.PubMedPubMedCentral
41.
Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med. 2016;10(2):93-103.PubMed
42.
Winograd RP, Presnall N, Stringfellow E, Wood C, Horn P, Duello A, et al. The case for a medication first approach to the treatment of opioid use disorder. Am J Drug Alcohol Abuse. 2019;45(4):333-40.PubMed
43.
Winograd RP, Wood CA, Stringfellow EJ, Presnall N, Duello A, Horn P, et al. Implementation and evaluation of Missouri’s Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs. J Subst Abuse Treat. 2019 Jun 26.
44.
Montgomery AE, Hill L, Culhane DP, Kane V. Housing First implementation brief. Washington, DC: VA National Center on Homelessness Among Veterans, U.S. Department of Veterans Affairs, 2014.
45.
Smelson D, Farquhar I, Fisher W, Pressman K, Pinals DA, Samek B, et al. Integrating a co-occurring disorders intervention in drug courts: an open pilot trial. Community Ment Health J. 2019;55(2):222-31.PubMed
46.
Westreich LM. Use of medication-assisted treatment in the justice system: a medical perspective. Journal for Advancing Justice. 2019;2:5-19.
47.
Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63-75.PubMed
48.
Zhu Y, Evans EA, Mooney LJ, Saxon AJ, Kelleghan A, Yoo C, et al. Correlates of long-term opioid abstinence after randomization to methadone versus buprenorphine/naloxone in a multi-site trial. J Neuroimmune Pharmacol. 2018;13(4):488-97.PubMedPubMedCentral
49.
Clark RE, Baxter JD, Aweh G, O’Connell E, Fisher WH, Barton BA. Risk factors for relapse and higher costs among Medicaid members with opioid dependence or abuse: opioid agonists, comorbidities, and treatment history. J Subst Abuse Treat. 2015;57:75-80.PubMedPubMedCentral
50.
Muthulingam D, Bia J, Madden LM, Farnum SO, Barry DT, Altice FL. Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support. J Subst Abuse Treat. 2019;100:18-28.PubMedPubMedCentral
51.
Andrilla CHA, Moore TE, Patterson DG. Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: recommendations from rural physicians. J Rural Health. 2019;35(1):113-21.PubMed
52.
Gallagher JR, Marlowe DB, Minasian RM. Participant perspectives on medication-assisted treatment for opioid use disorders in drug court. Journal for Advancing Justice. 2019;2:39-54.
53.
Dorman A, Badeti J, Boros A. An exploration of knowledge, opinions, and stigma regarding medication-assisted treatment among treatment and criminal justice professionals. Journal for Advancing Justice. 2019;2:93-108.
54.
Dineen KK. Addressing prescription opioid abuse concerns in context: synchronizing policy solutions to multiple complex public health problems. Law & Psychol Rev. 2016;40:1.
55.
Johnson B, Richert T. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities. Harm Reduct J. 2019;16(1):31.PubMedPubMedCentral
56.
Havnes IA, Clausen T, Middelthon AL. ‘Diversion’ of methadone or buprenorphine: ‘harm’ versus ‘helping’. Harm Reduct J. 2013;10:24.PubMedPubMedCentral
57.
Harris M, Rhodes T. Methadone diversion as a protective strategy: the harm reduction potential of ‘generous constraints’. Int J Drug Policy. 2013;24(6):e43-50.PubMed
58.
Larance B, Lintzeris N, Ali R, Dietze P, Mattick R, Jenkinson R, et al. The diversion and injection of a buprenorphine-naloxone soluble film formulation. Drug Alcohol Depend. 2014;136:21-7.PubMed
59.
Johnson B, Richert T. Diversion of methadone and buprenorphine from opioid substitution treatment: a staff perspective. J Psychoactive Drugs. 2014;46(5):427-35.PubMed
60.
Richert T, Johnson B. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden. Harm Reduct J. 2015;12:1.PubMedPubMedCentral
61.
Rubinsky AD, Chen C, Batki SL, Williams EC, Harris AH. Comparative utilization of pharmacotherapy for alcohol use disorder and other psychiatric disorders among U.S. Veterans Health Administration patients with dual diagnoses. J Psychiatr Res. 2015;69:150-7.PubMed
Metadata
Title
Barriers to Medications for Opioid Use Disorder Among Veterans Involved in the Legal System: a Qualitative Study
Authors
Andrea K. Finlay, PhD
Erica Morse, MA
Matthew Stimmel, PhD
Emmeline Taylor, BS
Christine Timko, PhD
Alex H. S. Harris, PhD
David Smelson, PsyD
Mengfei Yu, MS
Jessica Blue-Howells, MSW
Ingrid A. Binswanger, MD
Publication date
01-09-2020
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine / Issue 9/2020
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-020-05944-6

Other articles of this Issue 9/2020

Journal of General Internal Medicine 9/2020 Go to the issue

Viewpoint

COVID-19 Is Infecting Our Clinical Acumen

Original Research

An Effectiveness Evaluation of a Primary Care–Embedded Clinical Pharmacist–Led Intervention Among Blacks with Diabetes

Perspective

Trying Times and Trying Out Solutions: Intimate Partner Violence Screening and Support for Women Veterans During COVID-19

Original Research

The Association Between Physician Race/Ethnicity and Patient Satisfaction: an Exploration in Direct to Consumer Telemedicine

Concise Research Report

Charlson Comorbidity Index Score and Risk of Severe Outcome and Death in Danish COVID-19 Patients

Perspective

Harnessing the Power of Hospitalists in Operational Disaster Planning: COVID-19

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits